Cutera(US:CUTR)2020-02-27 02:33Financial Data and Key Metrics Changes - For fiscal 2019, total revenue was $181.7 million, a 12% increase over fiscal 2018, with U.S. revenue growing 4% and international revenue growing 24% [27] - In Q4 2019, total revenue grew 14% to $51.8 million from $45.5 million in Q4 2018, with U.S. revenue growing 11% and international revenue growing 19% [28] - Non-GAAP gross profit for fiscal 2019 was $100.2 million, up from $86.4 million in fiscal 2018, with non-GAAP gross margin improving to 55.2% from 53.1% [32] - Non-GAAP gross profit for Q4 2019 was $29.4 million compared to $24 million in Q4 2018, with non-GAAP gross margin at 56.7% versus 52.8% [33] Business Line Data and Key Metrics Changes - The truSculpt body sculpting franchise grew 52% in Q4 2019 compared to Q4 2018, contributing significantly to revenue growth [17] - Recurring revenue, which includes global service contracts, consumables, and skincare products, grew 37% in fiscal 2019 to $41.2 million, representing 23% of total revenue [29] - Consumable revenue grew 132% in fiscal 2019 to $9.6 million, with Q4 2019 consumable revenue growing over 98% to $2.5 million compared to Q4 2018 [30][31] Market Data and Key Metrics Changes - International systems revenue grew 18% in Q4 2019, benefiting from investments in commercial talent and sales infrastructure [19] - Strong growth was noted in key international markets, particularly in Japan, Australia, New Zealand, and Europe [27][28] Company Strategy and Development Direction - The company is focused on delivering consistent improvement in cost structures and expanding its product pipeline, particularly in the body sculpting market [7][9] - Investments in the international commercial team have led to growth exceeding market rates, indicating a strategic focus on international expansion [11] - The company aims to leverage its R&D capabilities to drive innovation and maintain a competitive edge in the aesthetics market [51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2020, targeting total revenue between $194 million and $200 million, representing a 7% to 10% increase over fiscal 2019 [42] - The company is optimistic about the impact of new product launches and the strength of its international operations on future growth [20][44] Other Important Information - The company has made changes to its North American sales organization, assessing the impact of recent departures and adjusting revenue plans accordingly [14] - Cash and equivalents at the end of fiscal 2019 were approximately $33.9 million, slightly down from $35.6 million at the end of fiscal 2018 [40] Q&A Session Summary Question: How does the revenue guidance look for U.S. versus international markets? - Management expects international growth to outpace U.S. growth in 2020, driven by strong demand for new products like truSculpt flex [46][47] Question: What are the expectations for adjusted EBITDA margins in 2020? - Management anticipates a stronger contribution from operating margins, with gross margin expansion being a key driver [48][49] Question: What is the company's exposure to the coronavirus from a supply chain perspective? - Management believes the company has limited exposure due to sourcing components primarily in the U.S. and is actively monitoring the situation [53][54] Question: Can you clarify the components of recurring revenue? - Recurring revenue includes global service contracts, consumables, and skincare products, with consumables being the fastest-growing segment [59][61] Question: What is the status of the sales organization following recent departures? - An interim Vice President of Sales has been appointed, and the company is actively searching for a permanent replacement while promoting from within [65][67]